Severe disease reactivation in four patients with relapsing–remitting multiple sclerosis after fingolimod cessation-Reference-Cited by-同舟云学术

Severe disease reactivation in four patients with relapsing–remitting multiple sclerosis after fingolimod cessation

Published:2015-05 Issue: Volume:282 Page:118-122
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Berger Benjamin,Baumgartner Annette,Rauer Sebastian,Mader Irina,Luetzen Niklas,Farenkopf Ulrich,Stich Oliver

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,Immunology,Immunology and Allergy

Reference21 articles.

1. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab;Baumgartner;Int. J. Neurosci.,2012

2. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study;Boriello;Eur. J. Neurol.,2012

3. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis;Cohen;N. Engl. J. Med.,2010

4. Pooled efficacy data demonstrate that fingolimod reduces multiple sclerosis relapse rate with no evidence of rebound after discontinuing treatment. Abstract book;De Vera,2010

5. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study;Fox;Neurology,2014

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recurring disease activity in relapsing remitting multiple sclerosis: The multicenter RDA-RMS study;Multiple Sclerosis and Related Disorders;2024-08

2. Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis;Clinical Neurology and Neurosurgery;2024-08

3. Beyond conventional therapies: IVIG in treating severe fingolimod-rebound in a postpartum patient with MS;BMJ Case Reports;2024-07

4. Risk of T2 lesions when discontinuing fingolimod: a nationwide predictive and comparative study;Brain Communications;2023-12-28

5. Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice;International Immunopharmacology;2023-12